GeneralBreaking NewsBreakingLatest News
World's First Cancer Vaccine Cuts Melanoma Recurrence Risk By 42%, Cancer Spread Risk By 38%
Sentiment: PositiveHigh Priority
What Happened?
A Phase 3 trial of a personalized mRNA cancer vaccine by Moderna and Merck showed a 42% reduction in melanoma recurrence risk and a 38% reduction in cancer spread risk when combined with immunotherapy.
Key points
- The Phase 3 INTerpath-001 trial included 1,137 patients with high-risk melanoma.
- Patients received either the vaccine intismeran autogene with Keytruda or a placebo with Keytruda.
- After two years, 82.2% of patients receiving the vaccine were cancer-free compared to 70% of those receiving Keytruda alone.
- The combination treatment met its primary and secondary endpoints for survival.
- No new safety concerns were reported in the trial.
Key insights
- The success of this vaccine could lead to new treatment paradigms in cancer care.
- Personalized vaccines may become a standard approach in oncology.
- The findings could prompt regulatory discussions for faster approval of innovative cancer treatments.
Why it matters
This breakthrough could significantly improve treatment options for melanoma patients post-surgery.
Entities
Moderna· CompanyMerck· CompanyKeytruda· ProductEuropean Society for Medical Oncology· Event
Source
Times Now
